Halted trial tests new drug cocktail for aggressive blood disorder
NCT ID NCT04812548
Summary
This study aimed to test the safety and initial effectiveness of a new drug, sabatolimab, when combined with two existing drugs (azacitidine and venetoclax) for adults with high-risk MDS who could not receive intensive chemotherapy or a stem cell transplant. The trial was terminated early by the sponsor after enrolling only 20 participants in the initial safety phase, so the full effectiveness of the combination was never evaluated. The main goals were to check for serious side effects and see if the treatment could put the disease into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Brasschaat, 2930, Belgium
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Nice, 06202, France
-
Novartis Investigative Site
Düsseldorf, 40479, Germany
-
Novartis Investigative Site
Stuttgart, 70376, Germany
-
Novartis Investigative Site
Alexandroupoli, Evros, 681 00, Greece
-
Novartis Investigative Site
Pátrai, 265 00, Greece
-
Novartis Investigative Site
Nyíregyháza, 4400, Hungary
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
Conditions
Explore the condition pages connected to this study.